MARKET

CINGW

CINGW

Cingulate
NASDAQ
0.0184
+0.0003
+1.66%
Closed 12:33 06/09 EDT
OPEN
0.0283
PREV CLOSE
0.0181
HIGH
0.0283
LOW
0.0184
VOLUME
5.83K
TURNOVER
--
52 WEEK HIGH
0.1750
52 WEEK LOW
0.0154
MARKET CAP
--
P/E (TTM)
-0.0043
1D
5D
1M
3M
1Y
5Y
1D
Cingulate director Jeff Hargroves acquires 97,276 common shares for $490,271.04
PUBT · 22h ago
Cingulate files Form 3 initial beneficial ownership statement for director Jeff Hargroves
PUBT · 22h ago
Weekly Report: what happened at CINGW last week (0601-0605)?
Weekly Report · 1d ago
Cingulate says FDA CRL for CTx-1301 cites CMC requests, no clinical safety or efficacy concerns
PUBT · 06/02 12:13
Cingulate gets FDA complete response letter for ADHD drug CTx-1301 on CMC issues
PUBT · 06/02 12:03
CINGULATE - HAS NEARLY $30 MLN IN CASH RESERVES TO FUND OPERATIONS INTO 2027
Reuters · 06/02 12:00
NASDAQ TRADE HALT <CING.O> HALT NEWS PENDING AT 07:55 AM
Reuters · 06/02 11:55
Weekly Report: what happened at CINGW last week (0525-0529)?
Weekly Report · 06/01 09:19
More
About CINGW
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Webull offers Cingulate Inc stock information, including NASDAQ: CINGW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CINGW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CINGW stock methods without spending real money on the virtual paper trading platform.